Ушбу иш иқтибос қилган ишлар

189 та иш

Иш: Innovations in cancer immunotherapy: A comprehensive overview of recent breakthroughs and future directions

Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles
Marina Colombo, Graça Raposo, Clotilde Théry
Шарҳ мақола201412 иқтибос
ABI
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
Шарҳ мақола20127 иқтибос
ABI
Extracellular vesicles: Exosomes, microvesicles, and friends
Graça Raposo, Willem Stoorvogel
Шарҳ мақола20135 иқтибос
ABI
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje, Jesús G. Berdeja, Yi Lin +20
Мақола20194 иқтибос
ABI
CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
Wenyan Fu, Changhai Lei, Shuowu Liu +12
Мақола20194 иқтибос
ABI
Delivery technologies for cancer immunotherapy
Rachel Riley, Carl H. June, Róbert Langer +1
Шарҳ мақола20193 иқтибос
ABI
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Philip W. Kantoff, Celestia S. Higano, Neal D. Shore +10
Мақола20103 иқтибос
ABI
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp, Michael Kalos, David M. Barrett +10
Мақола20133 иқтибос
ABI
CTLA-4 and PD-1 Pathways
Elizabeth I. Buchbinder, Anupam M. Desai
Шарҳ мақола20153 иқтибос
ABI
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dai Fukumura, Jonas Kloepper, Zohreh Amoozgar +2
Шарҳ мақола20183 иқтибос
ABI
Macrophages as regulators of tumour immunity and immunotherapy
David G. DeNardo, Brian Ruffell
Шарҳ мақола20193 иқтибос
ABI
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Ju‐Yeun Lee, Hyun Tae Lee, Woo‐Ri Shin +11
Мақола20162 иқтибос
ABI
Going viral with cancer immunotherapy
Brian D. Lichty, Caroline J. Breitbach, David F. Stojdl +1
Шарҳ мақола20142 иқтибос
ABI
Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Caroline J. Breitbach, Rozanne Arulanandam, Naomi De Silva +15
Мақола20132 иқтибос
ABI
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio +26
Мақола20152 иқтибос
ABI
Viral vectors: a look back and ahead on gene transfer technology.
Laura Vannucci, Michele Lai, Flavia Chiuppesi +2
Мақола20132 иқтибос
ABI
Сарлавҳасиз
Бошқа2 иқтибос
ABI
Dendritic cells in cancer immunology and immunotherapy
Stefanie K. Wculek, Francisco J. Cueto, Adriana M. Mujal +3
Шарҳ мақола20192 иқтибос
ABI
Injectable dual-scale mesoporous silica cancer vaccine enabling efficient delivery of antigen/adjuvant-loaded nanoparticles to dendritic cells recruited in local macroporous scaffold
Thanh Loc Nguyen, Bong Geun, Young‐Jin Choi +2
Мақола20202 иқтибос
ABI
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen, Ira Mellman
Шарҳ мақола20132 иқтибос
ABI
Cancer immunotherapy comes of age
Ira Mellman, George Coukos, Glenn Dranoff
Шарҳ мақола20112 иқтибос
ABI
The future of immune checkpoint therapy
Padmanee Sharma, James P. Allison
Шарҳ мақола20152 иқтибос
ABI
Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study
Mei‐Hwei Chang, San‐Lin You, Chien‐Jen Chen +9
Мақола20092 иқтибос
ABI
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Antonio Di Stasi, Siok‐Keen Tey, Gianpietro Dotti +17
Мақола20112 иқтибос
ABI
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.
G. Fyfe, Richard I. Fisher, S A Rosenberg +3
Мақола19952 иқтибос
ABI